Osteoporosis: Pathophysiology and clinical aspects

Principles of Osteoimmunology: Molecular Mechanisms and Clinical Applications

Volumn 9783709105207, Issue , 2012, Pages 137-167

  Mikosch, Peter ^a  

^a AUVA Soziale Unfallversicherung   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84930606426     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-7091-0520-7_7     Document Type: Chapter

References (99)

1. Chrischilles EA, Butler CD, Davis CS, Wallace RB (1991) A model of lifetime osteoporosis impact. Arch Intern Med 151:2026-2032
2. Lohmann R, Haid K, Stöckle U, Raschke M (2007) Epidemiologie und Perspektiven der Alterstraumatologie [Epidemiology and perspectives in traumatology of the elderly] Unfallchirurg 110:553-560
3. U. S. Dept. Of Health and Human Services, Centers of Disease Control and Prevention, National Center for Health Statistics (1998) National Health and Nutrition Examination Surgery III, 1988-1994. Hyattsville, MD
4. Tosteson A, Solomon D, King AB, et al. (2005) Projections of osteoporosis fractures and costs by skeletal site in the USA. Bone Miner Res 20:S21
5. Häussler B, Gothe H, Göl D, Glaeske G, Pientka L, Felsenberg D (2007). Epidemiology, treatment and costs of osteoporosis in Germany - the BoneEVA Study. Osteoporos Int 18:77-84
6. Konnopka A, Jerusel N, König HH (2009) The health and economic consequences of osteopeniaand osteoporosis-attributable hip fractures in Germany: estimation for 2002 and projection until 2050. Osteoporos Int 20:1117-1129
7. Pietschmann P, Azizi-Semrad U, Pils K, Fahrleitner-Pammer A, Resch H, Dobnig H (2010) Pharmacologic undertreatment of osteoporosis in Austrian nursing homes and senior's residences. Wien Klin Wochenschr, 160:532-527
8. Wright RM (2007) Use of osteoporosis medications in older nursing facility residents. J Am Med Dir Assoc 8:453-457
9. Haaland DA, Cohen DR, Kennedy CC, Khalidi NA, Adachi JD, Papaioannou A (2009) Closing the osteoporosis care gap: increased osteoporosis awareness among geriatrics and rehabilitation teams. BMC Geriatr 9:28. doi10.1186/1471-2318-9-28
10. Metge CJ, Leslie WD, Manness LJ, Yogendran M, Yuen CK, Kvern B (2008) Maximizing Osteoporosis Management in Manitoba Steering Committee. Postfracture care for older women: gaps between optimal care and actual care. Can Fam Physician 54:1270-1276
11. Papaioannou A, Kennedy CC, Ioannidis G et al. (2008) CaMos Research Group: The osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis Study. Osteoporos Int 19:581-587
12. Giangregorio LM, Jantzi M, Papaioannou A, Hirdes J, Maxwell CJ, Poss JW (2009) Osteoporosis management among residents living in long-term care. Osteoporos Int 20:1471-1478
13. Kamal HK (2005) Secondary prevention of hip fractures among hospitalized elderly: are we doing enough? J Clin Rheumatol 11:68-71
14. Teitelbaum SL (2007) Osteoclasts: What do they do and how do they do it? Am J Path 170:427-435
15. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785-795
16. Walsh MC, Kim N, Kadono Y, Rho J, Lee SY, Lorenzo J, Choi Y (2006) Osteoimmunology: Interplay between the immune system and bone metabolism. Annu Rev Immunol 24:33-63
17. Rothe A, Power BE, Hudson PJ (2008) Therapeutic advances in rheumatology with the use of recombinant proteins. Nat Clin Pract Rheumatol 4:605-614
18. Sipos W, Pieschmann P, Rauner M (2008) Stategies for novel therapeutic approaches targeting cytokines and signaling pathways of osteoclasto- and osteoblastogenensis in the fight against immune-mediated bone and joint diseases. Curr Med Chem 15:127-136
19. Yamaguchi A, Komori T, Suda T (2000) Regulation of osteoblast differentiation mediated by bone morphogenetic proteins, hedgehogs, and Cbfa1. Endor Rev 21:393-411
20. Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337-342
21. Calvi LM, Adams GB, Weibrecht KW et al. (2003) Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425:841-846
22. Calvi LM, Sims NA, Hunzelman JL, Knight MC, Giovannetti A, Saxton JM, Kronenberg HM, Baron R, Schipani E (2001) Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells defferentially affects cortical and trabecular bone. J Clin Invest 107:277-286
23. Lecka-Cernik B, Moerman EJ, Grant DF, Lehmann JM, Manolagas SC, Jilka RL (2002) Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 143:2376-2384
24. Kim SW, Her SJ, Kim SY, Shin CS (2005) Ectopic everexpression of adipogenic transcription factors induces transdifferentiation of MC3T3-E1 osteoblasts. Biochem Biophys Res Commun 327:811-819
25. Ziegler-Heitbrock L (2007) The CD14+CD16+ blood monocytes: Their role in infection and inflammation. J Leukoc Biol 81:584-592
26. Wong BR, Besser D, Kim N, Arron JR, Vologodskaia M, Hanafusa H, Choi Y (1999). TRANCE, a TNF family member, activates Akt/PKB trough a signaling complex involving TRAF6 and s-src. Mol Cell 4:1041-1049
27. Yagi M, Miyamoto T, Toyama Y, Suda T (2006) Role of DC-STAMP in cellular fusion of osteoclasts and macrophage giant cells. J Bone Miner Metab 24:355-358
28. Zwerina J, Redlich K, Polzer K, Joosten L, Kronke G, Distler J, Hess A, Pundt N, Pap T, Hoffmann O, Gasser J, Scheinecker C, Smolen JS, Van Den Berg W, Schett G (2007) TNF-induced structural joint damange is dediated by IL-1. Proc Natl Acad Sci USA 104:11742-11747
29. Polzer K, Joosten L, Gasser J, Distler JH, Ruiz G, Baum W, Redlich K, Bobacz K, Smolen JS, Van Den Berg W, Schett G, Zwerina J (2010) IL-1 is essential for systemic inflammatory bone loss. Ann Rheum Dis 69:284-290
30. Rho J, Takami M, Choi Y (2004) Osteoimmunology. Interactions of the immune and skeletal systems. Mol Cells 17:1-9
31. Miyamoto T, Ohnada O, Arai F, Iwamoto K, Okada S, Tagagi K, Anderson DM, Suda T (2001) Bifurcation of osteoclasts and dentritic cells from common progenitors. Blood 98:2544-2554
32. Rivollier A, Mazzorana M, Tebib J, Piperno M, Aitsiselmi T, Rabourdin-Combe C, Jurdic P, Servet-Delprat C (2004) Immature dentritic cell transdifferentiation into osteoclasts: a novel pathway sustained by the rheumatoid arthritis microenvironment. Blood 104:4029-4037
33. Alnaeeli M, Park J, Mahamed D, Penninger JM, Teng YT (2007) Dentritic cells at the osteoimmune interface: implications for inflammation-induced bone loss. J Bone Miner Res 22:775-780
34. Jones DH, Kong YY, Penninger JM (2002) Role of RANKL and RANK in bone loss and arthritis. Ann Rheum Dis 61(Suppl 2): ii32-39
35. Takayanagi H (2009) Osteoimmunology and the effects of the immune system on bone. Nat Rev Rheumatol 5:667-676
36. Sato S, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, Tanaka S, Kodama T, Akira S, Iwakura Y, Cua DJ, Takayanagi H (2006) Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 203:2673-2682
37. Won HY, Lee JA, Park ZS, Song JS, Kim HY, Jang SM, Yoo SE, Rhee Y, Hwang ES, Bae MA (2011) Prominent Bone Loss Mediated by RANKL and IL-17 Produced by CD4+ T Cells in TallyHo/JngJ Mice. PLoS One 6:e18168
38. Pene J, Chevalier S, Preisser L, Venereau E, Guilleux MH, Ghannam S, Moles JP, Danger Y, Ravon E, Lesaux S, Yssel H, Gascan H (2008) Chronically inflamed human tissue are infiltrated by highly differentiated Th17 lymphocytes. J Immunol 180:7423-7430
39. Gaffen SL, Hajishengallis G (2008) A new inflammatory cytokine on the block: re-thinking periodontal disease and the Th1/Th2 paradigm in the context of Th17 cells and IL-17. J Dent Res 87:817-828
40. Colin EM, Asmawidjaja PS, Van Hamburg JP, Mus AM, Van Driel M, Hazes JM, Van Leeuwen JP, Lubberts E (2010) 1, 25-dihydroxyvitamin D3 modulates Th17 polarization and interleukin-22 expression by memory T cells from patients with early rheumatoid arthritis. Arthritis Rheum 62:132-142.
41. Ghishan FK, Kiela PR (2011). Advances in the understanding of mineral and bone metabolism in inflammatory bowel diseases. Am J Physiol Gastrointest Liver Physiol 300:G191-201
42. Saltel F, Chabadel A, Zhao Y, Lafage-Proust MH, Clézardin P, Jurdic P, Bonnelye E (2006) Transmigration: a new property of mature multinucleated osteoclasts. J Bone Miner Res 21:1913-1923
43. Josien R, Wong BR, Li HL, Steinman RM, Choi Y (1999) TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. J Immunol 162:2562-2568
44. Geijtenbeek TB, Van Vliet SJ, Engering A, 't Hart BA, Van Kooyk Y (2004) Self- and non-selfrecognition by C-type lectins on dendritic cells. Annu Rev Immunol 22:33-54
45. Vojdani A, Erde J (2006) Regulatory T cells, a potent immunoregulatory target for CAM researchers: the ultimate antagonist (I). Evid Based Complement Alternat Med 3:25-30
46. Vojdani A, Erde J (2006) Regulatory T Cells, a Potent Immunoregulatory Target for CAM Researchers: Modulating Allergic and Infectious Disease Pathology (II). Evid Based Complement Alternat Med 3:209-215
47. Vojdani A, Erde J (2006) Regulatory T Cells, a Potent Immunoregulatory Target for CAM Researchers: Modulating Tumor Immunity, Autoimmunity and Alloreactive Immunity (III). Evid Based Complement Alternat Med 3:309-316
48. Clowes JA, Riggs BL, Khosla S (2005) The role of the immune system in the pathophysiology of osteoporosis. Immunol Rev 208:207-227
49. Cheroutre H (2004) Starting at the beginning: new perspectives on the biology of mucosal T cells. Annu Rev Immunol 22:217-246
50. Bengmark S (2004) Acute and "chronic" phase reaction-a mother of disease. Clin Nutr 23:1256-1266
51. Li Y, Toraldo G, Li A, Yang X, Zhang H, Qian WP, Weitzmann MN (2007) B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood 109:3839-3848
52. Manabe N, Kawaguchi H, Chikuda H, Miyaura C, Inada M, Nagai R, Nabeshima Y, Nakamura K, Sinclair AM, Scheuermann RH, Kuro-o M (2001) Connection between B lymphocyte and osteoclast differentiation pathways. J Immunol. 167:2625-2631
53. Breuil V, Ticchioni M, Testa J, Roux CH, Ferrari P, Breittmayer JP, Albert-Sabonnadière C, Durant J, De Perreti F, Bernard A, Euller-Ziegler L, Carle GF (2010) Immune changes in postmenopausal osteoporosis: the Immunos study. Osteoporos Int. 21:805-814
54. Xiao P, Chen Y, Jiang H, Liu YZ, Pan F, Yang TL, Tang ZH, Larsen JA, Lappe JM, Recker RR, Deng HW (2008) In vivo genome-wide expression study on human circulating B cells suggests a novel ESR1 and MAPK3 network for postmenopausal osteoporosis. J Bone Miner Res. 23:644-654
55. Christiansen C, Christiansen MS, Transbol I (1981) Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet 1:459-461
56. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, Lubahn DB, Korach KS (1994) Rstrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 331:1056-1061
57. Eriksen EF, Colvard DS, Berg NJ, Graham ML, Mann KG, Spelsberg TC, Riggs BL (1988) Evidence of estrogen receptors in normal human osteoblast like cells. Science 241:84-86
58. Komm BS, Terpening CM, Benz DJ, Graeme KA, O'Malley BW, Haussler MR (1988) Estrogen binding receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells. Science 241:81-84
59. Oursler MI, Osdoby P, Pyfferoen J, Riggs BL, Spelsberg TC (1998) Avian osteoclasts as estrogen target cells. Proc Natl Acad Sci USA 88:6613-6617
60. Saika M, Inoue D, Kido S, Matsumoto T (2001) 17beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha. Endocrinology 142:2205-2212
61. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DI, Riggs BL (2003) Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 111:1120-1122
62. Krum SA, Miranda-Carboni GA, Hauschka PV, Carroll JS, Lane TF, Freedman LP, Brown M (2008) Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. EMBO J 27:535-545
63. Heaney RP, Recker RR, Saville PD (1978) Menopause changes in calcium balance performance. J Lab Clin Med 92:953-963
64. McKane WR, Khosla S, Burritt MF, Kao PC, Wilson DM, Ory SJ, Riggs BL (1995) Mechanism of renal calcium conservation with estrogen replacement therapy in women in early menopause. A clinical research center study. J Clin Endocrinol Metab 80:3458-2464
65. Gennari C, Agnusdei D, Nardi P, Civitelli R (1990) Estrogen preserves a normal intestinal responsiveness to 1, 25-dihydroxyvitamin D3 in oophorectomized women. J Clin Endocrinl metab 71:1288-1293
66. Cosman F, Shen V, Xie F, Seibel M, Ratcliffe A, Lindsay R (1993). Estrogen protection against bone resorbing effects of parathyroid hormone infusion. An Intern Med 118:337-343
67. Arron JR, Choi Y (2000) Bone versus immune system. Nature 408:535-536
68. Gallagher JC, Riggs BL, Eisman J, Hamstra A, Arnaud SB, DeLuca HF (1979) Intestinal calcium absorption and serum vitamin D metabolites in normal subjects and osteoporotic patients: effects of age and dietary calcium. J Clin Invest 64:729-736
69. Pacifici R (2008) Estrogen deficiency, T cells and bone loss. Cell Immunol 252:68-80
70. Zaidi M (2007) Skeletal remodeling in health and disease. Nat Med 13:971-801
71. Franceschi C, Bonafe M, Valensin S, Olivieri F, Da Luca M, Ottaviani E, De Benedictitis G (2000) Inflamm-aging. An evolutionary perspective on immunosenescence. Ann NYAcad Sci 908:24-254
72. Pietschmann P, Grisar J, Thien R, Willhelm M, Kerschan-Schindl K, Preisinger E, Peterlik M (2001) Immune phenotype and intracellular cytokine production of peripheral blood mononuclear cells from postmenopausal patients with osteoporotic fractures. Exp Gerontol 36:1749-1759
73. Pacifici R (2007) T cells and post menopausal osteoporosis in murine models. Arthritis Res Ther 9:102
74. Robbie-Ryan M, Pacifici R, Weitzmann MN (2006) IL-7 drives T cell-mediated bone loss following ovariectomy. Ann NYAcad Sci 1068:348-351
75. Pietschmann P, Gollob E, Brosch S, Hahn P, Kudlacek S, Willhelm M, Woloszczuk W, Peterlik M, Tragl KH (2003) The effect of age and gender on cytokine production by human peripheral blood mononuclear cells and markers of bone metabolism. Exp Gerontol 38:1119-1127
76. Rauner M, Sipos W, Pietschmann P (2007) Osteoimmunology. Int Arch Allergy immunol 143:31-48
77. Gao Y, Grassi F, Ryan MR, Terauchi M, Page K, Yang X, Weitzmann MN, Pacifici R (2007) IFN-γ stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J Clin Invest 117:12-132
78. Messalli EM, Mainini G, Scaffa C, Cafiero A, Salzillo PL, Ragucci A, Cobellis L (2007) Raloxifene therapy interacts with serum osteoprotegerin in postmenopausal women. Maturitas 56:38-44
79. Katz S, Weinerman S (2010) Osteoporosis and gastrointestinal disease. Gastroenterol Hepatol (N Y) 6:506-517
80. Nielsen OH, Vainer B, Madsen SM, Seidelin JB, Heegaard NH (2000) Established and emerging biological activity markers of inflammatory bowel disease. Am J Gastroenterol 95:359-367
81. Tignor AS, Wu BU, Whitlock TL, Lopez R, Repas K, Banks PA, Conwell D (2010) High prevalence of low-trauma fracture in chronic pancreatitis. Am J Gastroenterol 105:2680-2686
82. Li Z, Lu WW, Chiu PK, Lam RW, Xu B, Cheung KM, Leong JC, Luk KD (2009) Strontiumcalcium coadministration stimulates bone matrix osteogenic factor expression and new bone formation in a large animal model. J Orthop Res 27:758-762
83. Fernández-García D, Muñoz-Torres M, Mezquita-Raya P, De La Higuera M, Alonso G, Reyes-García R, Ochoa AS, Ruiz-Requena ME, Luna JD, Escobar-Jiménez F (2008) Effects of raloxifene therapy on circulating osteoprotegerin and RANK ligand levels in post-menopausal osteoporosis. J Endocrinol Invest 31:416-421
84. Ozmen B, Kirmaz C, Aydin K, Kafesciler SO, Guclu F, Hekimsoy Z (2007) Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGFbeta1 and bone turnover markers in the treatment of postmenopausal osteoporosis. Eur Cytokine Netw 18:148-153
85. Gianni W, Ricci A, Gazzaniga P, Brama M, Pietropaolo M, Votano S, Patanè F, Aglianò AM, Spera G, Marigliano V, Ammendola S, Agnusdei D, Migliaccio S, Scandurra R (2004) Raloxifene modulates interleukin-6 and tumor necrosis factor-alpha synthesis in vivo: results from a pilot clinical study. J Clin Endocrinol Metab 89:6097-6099
86. Wutzl A, Gruber R, Brozek W, Hofbauer G, Lernbass I, Brosch S, Pietschmann P (2010) Mechanisms involved in the inhibition of osteoclast generation by the benzothiophene SERM LY117018. Wien Klin Wochenschr 122:626-632
87. Narayana Murthy PS, Sengupta S, Sharma S, Singh MM (2006) Effect of ormeloxifene on ovariectomy-induced bone resorption, osteoclast differentiation and apoptosis and TGF beta-3 expression. J Steroid Biochem Mol Biol 100:117-128
88. Kwak HB, Kirn JY, Kim KJ, Choi MK, Kim JJ, Kirn KM, Shin YI, Lee MS, Kim HS, Kim JW, Chun CH, Cho HJ, Hong GY, Juhng SK, Yoon KH, Park BH, Bae JM, Han JK, Oh J. Risedronate directly inhibits osteoclast differentiation and inflammatory bone loss. Bio1 Pharm Bull. 2009;32:1193-1198.
89. D'Amelio P, Gnmaldi A, Di Bella S, Tamone C, Brianza SZ, Ravazzoli MG, Bernabei P, Cristofaro MA, Pescmona GP, Isaia G. Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women. J Bone Miner Res 2008;23:373-379.
90. Dundar U, Kavuncu V, Cifici IH, Evcik D, Solak O, Cakir T. The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study. J Bone Miner Metab 2009;27:464-470.
91. D'Amelio P, Grimaidi A, Cristofaro MA, Ravazzoli M, Molinatti PA, Pescarmona GP, Isaia GC. Alendronate reduces osteoclast precursors in osteoporosis. Osteoporos Int. 2010;21:1741-1750.
92. Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Koukoulis G, Kita M, Avramidis A (2008) Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial. Horm Metab Res 40:281-285
93. Lim MJ, Kwon SR, Park SG, Park W (2010) Acute effects of intravenous administration of pamidronate in patients with osteoporosis. J Korean Med Sci 25:1277-1283
94. Bertoldo F, Pancheri S, Zenari S, Boldini S, Giovanazzi B, Zanatta M, Valenti MT, Dalle Carbonare L, Lo Cascio V (2010) Serum 25-hydroxyvitamin D levels modulate the acute-phase response associated with the first nitrogen-containing bisphosphonate infusion. J Bone Miner Res 25:447-454
95. Tankó LB (2007) Effect of RANKL-specific denosumab on osteoclast number and function: a potential friend or foe? Curr Opin Investig Drugs 8:830-835
96. Lewiecki EM, Miller PD, McClung MR, Cohen SB, Bolognese MA, Liu Y, Wang A, Siddhanti S, Fitzpatrick LA; AMG 162 Bone Loss Study Group (2007) Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res 22:1832-1841
97. Brennan TC, Rybchyn MS, Green W, Atwa S, Conigrave AD, Mason RS (2009) Osteoblasts play key roles in the mechanisms of action of strontium ranelate. Br J Pharmacol 157:1291-1300
98. Pepene CE, Seck T, Diel I, Minne HW, Ziegler R, Pfeilschifter J (2004) Influence of fluor salts, hormone replacement therapy and calcitonin on the concentration of insulin-like growth factor (IGF)-I, IGF-II and transforming growth factor-beta 1 in human iliac crest bone matrix from patients with primary osteoporosis. Eur J Endocrinol 150:81-91
99. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T (1999) Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 104:1363-1274